Suscribirse

The Association Between PICC Use and Venous Thromboembolism in Upper and Lower Extremities - 31/08/15

Doi : 10.1016/j.amjmed.2015.03.028 
M. Todd Greene, PhD, MPH a, b, c, Scott A. Flanders, MD a, b, Scott C. Woller, MD d, e, Steven J. Bernstein, MD, MPH a, b, c, Vineet Chopra, MD, MSc a, b, c,
a The Michigan Hospital Medicine Safety Consortium, Ann Arbor, Mich 
b Department of Internal Medicine, Division of General Medicine, University of Michigan School of Medicine, Ann Arbor, Mich 
c VA Ann Arbor Health Care System, Ann Arbor, Mich 
d Intermountain Medical Center, Murray, Utah 
e University of Utah School of Medicine, Salt Lake City, Utah 

Requests for reprints should be addressed to Vineet Chopra, MD, MSc, University of Michigan, North Campus Research Complex, 2800 Plymouth Rd, Building 16, #432W, Ann Arbor, MI 48109.

Abstract

Background

Peripherally inserted central catheters are associated with upper-extremity deep vein thrombosis. Whether they also are associated with lower-extremity deep vein thrombosis or pulmonary embolism is unknown. We examined the risk of venous thromboembolism in deep veins of the arm, leg, and chest after peripherally inserted central catheter placement.

Methods

We conducted a multicenter, retrospective cohort study of 76,242 hospitalized medical patients from 48 Michigan hospitals. Peripherally inserted central catheter presence, comorbidities, venous thrombosis risk factors, and thrombotic events within 90 days from hospital admission were ascertained by phone and record review. Cox proportional hazards models were fit to examine the association between peripherally inserted central catheter placement and 90-day hazard of upper- and lower-extremity deep vein thrombosis or pulmonary embolism, adjusting for patient-level characteristics and natural clustering within hospitals.

Results

A total of 3790 patients received a peripherally inserted central catheter during hospitalization. From hospital admission to 90 days, 876 thromboembolic events (208 upper-extremity deep vein thromboses, 372 lower-extremity deep vein thromboses, and 296 pulmonary emboli) were identified. After risk adjustment, peripherally inserted central catheter use was independently associated with all-cause venous thromboembolism (hazard ratio [HR], 3.16; 95% confidence interval [CI], 2.59-3.85), upper-extremity deep vein thrombosis (HR, 10.49; 95% CI, 7.79-14.11), and lower-extremity deep vein thrombosis (HR, 1.48; 95% CI, 1.02-2.15). Peripherally inserted central catheter use was not associated with pulmonary embolism (HR, 1.34; 95% CI, 0.86-2.06). Results were robust to sensitivity analyses incorporating receipt of pharmacologic prophylaxis during hospitalization.

Conclusions

Peripherally inserted central catheter use is associated with upper- and lower-extremity deep vein thrombosis. Weighing the thrombotic risks conferred by peripherally inserted central catheters against clinical benefits seems necessary.

El texto completo de este artículo está disponible en PDF.

Keywords : Deep vein thrombosis, Peripherally inserted central catheter, Venous thromboembolism


Esquema


 Funding: This study was funded by Blue Cross Blue Shield of Michigan. Other than research support, no compensation was received for this project. VC is supported by a career development award from the Agency for Healthcare Research and Quality (1K08HS022835-01). Blue Cross Blue Shield of Michigan supported data collection at each participating site and funded the data coordinating center but had no role in the study concept, interpretation of findings, or preparation, review, or final approval of the manuscript.
 Conflict of Interest: SAF discloses consultancies for the Institute for Healthcare Improvement and the Society of Hospital Medicine; royalties from Wiley Publishing; honoraria for various talks at hospitals as a visiting professor; grants from the Centers for Disease Control Foundation, Blue Cross Blue Shield of Michigan, and Michigan Hospital Association; and expert witness testimony. SCW discloses serving as a panelist for the American College of Chest Physicians Clinical Practice Guideline: Antithrombotic Therapy for Venous Thromboembolic Disease (AT10). SJB discloses memberships in the Blue Care Network Statewide Clinical Quality Committee and the Blue Care Network Medical Leadership Council.
 Authorship: All authors had access to the data and played a role in writing this manuscript.


© 2015  Publicado por Elsevier Masson SAS.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 128 - N° 9

P. 986 - septembre 2015 Regresar al número
Artículo precedente Artículo precedente
  • The Diabetes Shared Care Program and Risks of Cardiovascular Events in Type 2 Diabetes
  • Edy Kornelius, Jeng-Yuan Chiou, Yi-Sun Yang, Ying-Li Lu, Chiung-Huei Peng, Chien-Ning Huang
| Artículo siguiente Artículo siguiente
  • Increased Mortality Rates During Resident Handoff Periods and the Effect of ACGME Duty Hour Regulations
  • Joshua L. Denson, Matthew McCarty, Yixin Fang, Amit Uppal, Laura Evans

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.